| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Metastasis & Angiogenesis Research Group, University of Wales College of Medicine, Cardiff University, Cardiff, UK
1 Cancer Research Institute, University of South Alabama, Mobile, AL, USA
2 Pathology, University of Wales College of Medicine, Cardiff University, Cardiff, UK
3 Department of Surgery, St George Hospital, London, UK
(Requests for offprints should be addressed to W G Jiang; Email: jiangw{at}cf.ac.uk)
The CCN family members cysteine-rich 61 (Cyr61/CCN1), connective tissue growth factor (CTGF/CCN2) and nephroblastoma over-expressed (Nov/CCN3) play diverse roles in cells, are known to regulate cell growth, adhesion, matrix production and migration and are involved in endocrine-regulated pathways in various cell types. The role of these molecules in cancer remains controversial. In a cohort of 122 human breast tumours (together with 32 normal breast tissues) we have analysed the expression of all three CCN members at the mRNA and protein levels. Significantly higher levels of Cyr61 (P = 0.02), but low levels of CTGF and Nov, were seen in tumour tissues compared with normal tissues. Significantly raised levels of Cyr61 were associated with poor prognosis (P = 0.02), nodal involvement (P = 0.03) and metastatic disease (P = 0.016). Patients who died of breast cancer also had high levels of Cyr61. In contrast, CTGF in patients with poor prognosis (P = 0.021), metastasis (P = 0.012), local recurrence (P = 0.0024)and mortality (P = 0.0072)had markedly reduced levels. Similar to CTGF, low levels of Nov were also seen in patients with poor prognosis and mortality and with significantly decreased survival (P = 0.033 and P = 0.0146, respectively). This result was fully supported by immunohistochemical analysis of frozen sectioned tissues. While fibroblasts and endothelial cells generally expressed good levels of all three CCN proteins, highly invasive MDA MB 231 cells expressed lower levels of CTGF and Nov, but higher levels of Cyr61, than the less invasive MCF-7. It is concluded that members of the CCN family are differentially expressed and may play important but contrasting roles in the progressive nature of human breast cancer. While Cyr61 appears to act as a factor stimulating aggressiveness, CTGF and Nov may act as tumour suppressors.
This article has been cited by other articles:
|
|
 |
|
  A. Birgersdotter, K. R. N. Baumforth, W. Wei, P. G. Murray, J. Sjoberg, M. Bjorkholm, A. Porwit, and I. Ernberg Connective Tissue Growth Factor Is Expressed in Malignant Cells of Hodgkin Lymphoma but Not in Other Mature B-Cell Lymphomas Am J Clin Pathol, February 1, 2010; 133(2): 271 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Maggiolini and D. Picard The unfolding stories of GPR30, a new membrane-bound estrogen receptor J. Endocrinol., February 1, 2010; 204(2): 105 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-J. Xie, L.-Y. Xu, J.-Y. Wu, Z.-Y. Shen, Q. Zhao, Z.-P. Du, Z. Lv, W. Gu, F. Pan, X.-E Xu, et al. Involvement of CYR61 and CTGF in the Fascin-Mediated Proliferation and Invasiveness of Esophageal Squamous Cell Carcinomas Cells Am. J. Pathol., February 1, 2010; 176(2): 939 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E Ghayad, J. A Vendrell, I. Bieche, F. Spyratos, C. Dumontet, I. Treilleux, R. Lidereau, and P. A Cohen Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer J. Mol. Endocrinol., February 1, 2009; 42(2): 87 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Monnier, P. Farmer, G. Bieler, N. Imaizumi, T. Sengstag, G. C. Alghisi, J.-C. Stehle, L. Ciarloni, S. Andrejevic-Blant, R. Moeckli, et al. CYR61 and {alpha}V{beta}5 Integrin Cooperate to Promote Invasion and Metastasis of Tumors Growing in Preirradiated Stroma Cancer Res., September 15, 2008; 68(18): 7323 - 7331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Alvarez, A. Corvalan, J. C. Roa, P. Argani, F. Murillo, J. Edwards, R. Beaty, G. Feldmann, S.-M. Hong, M. Mullendore, et al. Serial Analysis of Gene Expression Identifies Connective Tissue Growth Factor Expression as a Prognostic Biomarker in Gallbladder Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2631 - 2638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Kuiper, J. M. Hughes, R. J. Van Geest, I. M. C. Vogels, R. Goldschmeding, C. J. F. Van Noorden, R. O. Schlingemann, and I. Klaassen Effect of VEGF-A on Expression of Profibrotic Growth Factor and Extracellular Matrix Genes in the Retina Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4267 - 4276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kikuchi, H. Tsuda, Y. Kanai, T. Kasamatsu, K. Sengoku, S. Hirohashi, J. Inazawa, and I. Imoto Promoter Hypermethylation Contributes to Frequent Inactivation of a Putative Conditional Tumor Suppressor Gene Connective Tissue Growth Factor in Ovarian Cancer Cancer Res., August 1, 2007; 67(15): 7095 - 7105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Sala-Torra, H. M. Gundacker, D. L. Stirewalt, P. A. Ladne, E. L. Pogosova-Agadjanyan, M. L. Slovak, C. L. Willman, S. Heimfeld, D. H. Boldt, and J. P. Radich Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia Blood, April 1, 2007; 109(7): 3080 - 3083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Chien, D. Yin, D. Gui, A. Mori, J. M. Frank, J. Said, D. Kusuanco, A. Marchevsky, R. McKenna, and H. P. Koeffler Suppression of Cell Proliferation and Signaling Transduction by Connective Tissue Growth Factor in Non-Small Cell Lung Cancer Cells Mol. Cancer Res., August 1, 2006; 4(8): 591 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Dornhofer, S. Spong, K. Bennewith, A. Salim, S. Klaus, N. Kambham, C. Wong, F. Kaper, P. Sutphin, R. Nacalumi, et al. Connective Tissue Growth Factor-Specific Monoclonal Antibody Therapy Inhibits Pancreatic Tumor Growth and Metastasis Cancer Res., June 1, 2006; 66(11): 5816 - 5827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Jiang, A. Raz, A. Douglas-Jones, and R. E. Mansel Expression of Autocrine Motility Factor (AMF) and Its Receptor, AMFR, in Human Breast Cancer J. Histochem. Cytochem., February 1, 2006; 54(2): 231 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Guo, S. Yang, C. Taylor, and G. E. Sonenshein Green Tea Polyphenol Epigallocatechin-3 Gallate (EGCG) Affects Gene Expression of Breast Cancer Cells Transformed by the Carcinogen 7,12-Dimethylbenz[a]Anthracene J. Nutr., December 1, 2005; 135(12): 2978S - 2986S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Jin, H. P. Kim, E. Ifedigbo, L. F. Lau, and A. M. K. Choi Cyr61 Protects against Hyperoxia-Induced Cell Death via Akt Pathway in Pulmonary Epithelial Cells Am. J. Respir. Cell Mol. Biol., September 1, 2005; 33(3): 297 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Jiang, G. Davies, T. A. Martin, C. Parr, G. Watkins, M. D. Mason, K. Mokbel, and R. E. Mansel Targeting Matrilysin and Its Impact on Tumor Growth In vivo: The Potential Implications in Breast Cancer Therapy Clin. Cancer Res., August 15, 2005; 11(16): 6012 - 6019. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
